NCT07052799 Aspirin Continuation or Interruption in Patients at Moderate Risk for Cardiovascular Events Undergoing Colonoscopy and/or Polypectomy
| NCT ID | NCT07052799 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Chinese University of Hong Kong |
| Condition | Myocardial Infarction (MI) |
| Study Type | INTERVENTIONAL |
| Enrollment | 2,514 participants |
| Start Date | 2026-02-10 |
| Primary Completion | 2030-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 2,514 participants in total. It began in 2026-02-10 with a primary completion date of 2030-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
One in 4 adults between 50 and 80 reports taking regular aspirin. The prevalence of aspirin uses increases with age as well as co-morbid vascular diseases. Patients with cardiovascular diseases are at risk of developing colorectal neoplasms. In patients undergoing screening colonoscopy, interruption of aspirin is believed to be associated with increased cardiovascular events. Continuation of aspirin can however be associated with an increased risk of post-polypectomy bleeding. International guidelines on periendoscopy management recommend the continuation of aspirin based on evidence from cohort studies, mostly retrospective, suggesting that the rate of bleeding is low. Cardiovascular complications from aspirin interruption can lead to disabilities and occasional deaths. The cardiovascular risks following aspirin continuation or interruption in endoscopy have not been well studied. There has been no randomized study to compare either strategy. Endoscopists are divided on their opinion on whether to stop or to continue aspirin. The proposed large randomized controlled trial (RCT) is powered to detect small differences in both outcomes. Findings from this RCT will address this important question and inform our clinical practice.
Eligibility Criteria
Inclusion Criteria: * patients receiving aspirin (80mg daily or more) for secondary prevention against cardiovascular diseases who require elective colonoscopy for colorectal cancer screening. Exclusion Criteria: * patients who received a coronary stent of any type within 6 months * patients who had a cardiovascular event within 3 months * patients who had concurrent use of anticoagulants (warfarin or NOAC) or other antiplatelet drugs (P2Y12 receptor antagonists) * patient with bleeding diathesis e.g., hemophilia, von Willebrand's disease or coagulopathy from liver cirrhosis * patient with terminal malignancies or medical illnesses. * patient who is unable or refuse to give consents
Contact & Investigator
James Yun Wong Lau, MD
PRINCIPAL INVESTIGATOR
Chinese University of Hong Kong
Frequently Asked Questions
Who can join the NCT07052799 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Myocardial Infarction (MI). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07052799 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 2,514 participants.
Is NCT07052799 currently recruiting?
Yes, NCT07052799 is actively recruiting participants. Contact the research team at laujyw@surgery.cuhk.edu.hk for enrollment information.
Where is the NCT07052799 trial being conducted?
This trial is being conducted at Hong Kong, Hong Kong.
Who is sponsoring the NCT07052799 clinical trial?
NCT07052799 is sponsored by Chinese University of Hong Kong. The principal investigator is James Yun Wong Lau, MD at Chinese University of Hong Kong. The trial plans to enroll 2,514 participants.